UCL Institute of Ophthalmology


DARC Phase II Clinical Trial

This  Phase 2, open-label, non-randomised, single site, clinical trial of ANX776 in patients diagnosed with:
  • Primary Open Angle Glaucoma/Glaucoma suspect/Ocular Hypertension (Glaucoma)
  • Down's syndrome (DS)
  • Age-Related Macular Degeneration (AMD)
  • Optic Neuritis (ON)
  • Healthy subjects (Controls)

is now complete but not completely analysed. The results from Glaucoma and AMD have now been published in collaboration with Novai Ltd, a start-up based on DARC Technology  (https://www.novai.co.uk/). DARC with AI was found to be predictive of disease progression in all 3 conditions.

graphic_abstract  Phase 2 DARC
  1. Cordeiro MF, Hill D, Patel R, Corazza P, Maddison J, Younis S. Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic. Prog Retin Eye Res. 2021 Jun 5;100976. doi: 10.1016/j.preteyeres.2021.100976.
  2. Corazza P, Maddison J, Bonetti P, Guo L, Luong V, Garfinkel A, Younis S, Cordeiro MF. Predicting wet age-related macular degeneration (AMD) using DARC (Detecting Apoptosing Retinal Cells) AI (artificial intelligence) technology). Expert Rev Mol Diagn. 2020 Dec 28:1-10. doi: 10.1080/14737159.2020.1865806.
  3. Normando EM, Yap TE, Maddison J, Miodragovic S, Bonetti P, Almonte M, Mohammad NG, Ameen S, Crawley L, Ahmed F, Bloom PA, Cordeiro MF. A CNN-aided method to predict glaucoma progression using DARC (Detection of Apoptosing Retinal Cells). Expert Rev Mol Diagn. 2020 Jul;20(7):737-748